$HCAT earnings report

Health Catalyst Reports Third Quarter 2026 Results. AlphAI read Health Catalyst's Third quarter 2026 filing as weak. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readHCAT · Third quarter 2026 · ended September 30, 2026

Health Catalyst Reports Third Quarter 2026 Results

↓Weak quarter

Third-quarter total revenue, gross profit, gross margin and Adjusted EBITDA declined year over year, while reported GAAP net income was driven largely by the $65.9 million gain on sale of the Vitalware Business.

Revenue
$56.3M
(26)% y/y
Technology, three months ended September 30, 2026
$40.7M
Gross margin · GAAP
31%
EPS · non-GAAP
$ (0.03)
Full year of 2026 outlook
$246 million to $249 million

Actuals vs. the company’s prior outlook

from its previous release
MetricGuidedReportedVerdict
Revenue, Q3 2026$55 million to $56 million for the third quarter of 2026$ 56,283 (in thousands)above
Adjusted EBITDA, Q3 2026$0 to $0.5 million for the third quarter of 2026$ 779 (in thousands)above

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$56.28M–(26)%
Gross profit, three months ended September 30, 2026GAAP$17.34M–(42)%
Gross margin, three months ended September 30, 2026GAAP31%––
Income from operations, three months ended September 30, 2026GAAP$50.14M––
Net income (loss) attributable to common stockholders, three months ended September 30, 2026GAAP$40.50M–282%
Net income (loss) per share, basic, three months ended September 30, 2026GAAP$ 0.54––
Net income (loss) per share, diluted, three months ended September 30, 2026GAAP$ 0.53––
Adjusted Gross Profit, three months ended September 30, 2026non-GAAP$24.91M–(38)%
Adjusted Gross Margin, three months ended September 30, 2026non-GAAP44%––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$779K–(94)%
Adjusted Cost of Revenue, three months ended September 30, 2026non-GAAP$31.37M––
Adjusted Operating Expenses, three months ended September 30, 2026non-GAAP$24.13M––
Adjusted Operating Expenses as a % of revenue, three months ended September 30, 2026non-GAAP43%––
Adjusted Net Income (Loss), three months ended September 30, 2026non-GAAP−$2.55M––
Adjusted Net Income (Loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ (0.03)––
Total revenue, nine months ended September 30, 2026GAAP$197.5M––
Income (loss) from operations, nine months ended September 30, 2026GAAP−$92.82M––
Net income (loss) attributable to common stockholders, nine months ended September 30, 2026GAAP−$111.1M––
Net cash provided by (used in) operating activities, nine months ended September 30, 2026GAAP$16.91M––

Segments

SegmentRevenueq/qy/y
Technology, three months ended September 30, 2026No segment-specific driver was provided.$40.69M––
Professional services, three months ended September 30, 2026No segment-specific driver was provided.$15.60M––
Technology, nine months ended September 30, 2026No segment-specific driver was provided.$138.9M––
Professional services, nine months ended September 30, 2026No segment-specific driver was provided.$58.58M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year of 2026 outlook

  • Revenue$246 million to $249 million
  • NoteAdjusted EBITDA of $18 million to $18.5 million.

Capital returns

  • Repurchase of common stock: $ — for the nine months ended September 30, 2026, compared with $ (5,000) (in thousands) for the nine months ended September 30, 2025.

What drove it

  • The divestiture of the Vitalware Business on July 31, 2026.
  • Headwinds related to the migration from DOS to Ignite.
  • Cost reduction initiatives partially offset the effects on total revenue, gross profit, gross margin, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA.
  • The $65.9 million gain on sale of the Vitalware Business largely drove third-quarter net income.

Concerns

  • Total revenue decreased (26)% year over year to $ 56,283 (in thousands).
  • Adjusted EBITDA decreased (94)% year over year to $ 779 (in thousands).
  • GAAP gross margin was 31%, compared with 39% in the prior-year quarter, and Adjusted Gross Margin was 44%, compared with 53%.
  • Professional services generated gross profit of $ (479) (in thousands) and gross margin of (3)% in the third quarter of 2026.
  • Adjusted Net Income (Loss) was $ (2,549) (in thousands), compared with $ 4,306 (in thousands).
  • Goodwill impairment was $ 122,548 (in thousands) for the nine months ended September 30, 2026.

What to watch

  • Client retention and the path to generating durable, profitable revenue.
  • Client churn or down-selling in connection with the migration to Ignite or otherwise.
  • The full-year 2026 outlook for total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million.
  • The effect of the Vitalware divestiture on revenue and profitability.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 53,746 (in thousands) as of September 30, 2026, compared with $ 50,814 (in thousands) as of December 31, 2025.
  • Short-term investments: $ 25,245 (in thousands) as of September 30, 2026, compared with $ 44,918 (in thousands) as of December 31, 2025.
  • Long-term debt, net of current portion: $ — as of September 30, 2026, compared with $ 151,624 (in thousands) as of December 31, 2025.
  • Repayment of debt: $ (163,960) (in thousands) for the nine months ended September 30, 2026.
  • Proceeds from sale of business: $ 144,455 (in thousands) for the nine months ended September 30, 2026.
  • Capitalization of internal-use software: $ (13,584) (in thousands) for the nine months ended September 30, 2026.
  • Purchases of property and equipment: $ (839) (in thousands) for the nine months ended September 30, 2026.
  • Net cash provided by investing activities: $ 149,382 (in thousands) for the nine months ended September 30, 2026.
  • Net cash used in financing activities: $ (163,331) (in thousands) for the nine months ended September 30, 2026.

Analysis

Health Catalyst reported third-quarter total revenue of $ 56,283 (in thousands), down (26)% from $ 76,323 (in thousands). Technology revenue was $ 40,686 (in thousands) and professional-services revenue was $ 15,597 (in thousands), compared with $ 52,051 (in thousands) and $ 24,272 (in thousands), respectively, in the prior-year quarter. The company said the year-over-year decline in total revenue primarily reflected the July 31, 2026 divestiture of the Vitalware Business and headwinds from the migration from DOS to Ignite, partly offset by cost reduction initiatives.

Profitability deteriorated in the operating business. GAAP gross profit fell (42)% to $ 17,345 (in thousands), with gross margin at 31% versus 39%. Adjusted Gross Profit fell (38)% to $ 24,913 (in thousands), and Adjusted Gross Margin was 44% versus 53%. Adjusted EBITDA declined (94)% to $ 779 (in thousands) from $ 12,000 (in thousands). Professional services posted $ (479) (in thousands) of gross profit and a (3)% gross margin, while technology generated $ 17,824 (in thousands) of gross profit and a 44% gross margin.

GAAP net income of $ 40,496 (in thousands), or $ 0.53 per diluted share, was not representative of underlying operating performance according to the release. It was largely driven by the $65.9 million gain on sale of the Vitalware Business. The quarter also included a $ 9,494 (in thousands) loss on extinguishment of debt. After the stated non-GAAP adjustments, Adjusted Net Income (Loss) was $ (2,549) (in thousands), or $ (0.03) per basic and diluted share. For the nine-month period, the company recorded a $ 122,548 (in thousands) goodwill impairment and a net loss of $ (111,067) (in thousands).

The sale of the Vitalware Business reshaped the balance sheet and financing profile. The company reported $ 144,455 (in thousands) of proceeds from sale of business and $ (163,960) (in thousands) of debt repayment for the nine months ended September 30, 2026. Long-term debt, net of current portion, was $ — as of September 30, 2026, versus $ 151,624 (in thousands) at December 31, 2025. Cash and cash equivalents were $ 53,746 (in thousands), and net cash provided by operating activities was $ 16,911 (in thousands) for the nine-month period.

Management reaffirmed full-year 2026 guidance for total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million. The key reported issues remain the revenue effects of the Vitalware divestiture, DOS-to-Ignite migration headwinds, client retention, professional-services gross profitability, and the conversion of cost reductions into durable profitability.

Management, verbatim

We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook.

Simeon Kohl, President and Chief Executive Officer

Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.

Simeon Kohl, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Fourth-quarter 2026 revenue and Adjusted EBITDA guidance
  • GAAP net income (loss) guidance
  • Free cash flow
  • Quarterly operating cash flow
  • Dividend declaration or payment
  • Prior-quarter comparisons for reported third-quarter metrics
  • Segment-specific year-over-year and sequential percentage changes
  • Segment-specific revenue drivers

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readHCAT · Second quarter 2026 · ended June 30, 2026

Health Catalyst reported second-quarter 2026 total revenue of $70,487 (in thousands), adjusted EBITDA of $9,919 (in thousands), and a GAAP net loss of $ (40,537) (in thousands).

→Mixed quarter

Revenue declined 13% year over year and the company recorded a GAAP net loss of $ (40,537) (in thousands), including $27,047 (in thousands) of goodwill impairment. Gross margin, adjusted gross margin, and adjusted EBITDA improved year over year, while management stated that second-quarter revenue exceeded the high end of its guidance.

Revenue
$70.5M
(13)% y/y
Technology
$48.8M
Gross margin · GAAP
40%
EPS · GAAP
$ (0.55)
Third quarter of 2026 and full year of 2026 outlook
$55 million to $56 million for the third quarter of 2026; $246 million to $249 million for the full year of 2026

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$70.49M–(13)%
Gross profitGAAP$27.86M–(8)%
Gross marginGAAP40%––
Total cost of revenue, excluding depreciation and amortizationGAAP$35.63M––
Sales and marketing expenseGAAP$10.36M––
Research and development expenseGAAP$11.03M––
General and administrative expenseGAAP$11.93M––
Depreciation and amortizationGAAP$10.98M––
Goodwill impairmentGAAP$27.05M––
Total operating expensesGAAP$71.34M––
Loss from operationsGAAP−$36.48M––
Interest and other expense, netGAAP−$3.74M––
Loss before income taxesGAAP−$40.22M––
Income tax provisionGAAP$315K––
Net lossGAAP−$40.54M–1%
Net loss per share, basic and dilutedGAAP$ (0.55)––
Weighted-average shares outstanding used in calculating net loss per share, basic and dilutedGAAP73.96M––
Adjusted Gross Profitnon-GAAP$35.84M–(10)%
Adjusted Gross Marginnon-GAAP51%––
Adjusted EBITDAnon-GAAP$9.92M–6%
Stock-based compensation expenseGAAP$2.71M––
Acquisition-related costs, netGAAP$1.96M––

Segments

SegmentRevenueq/qy/y
TechnologyTechnology revenue was $48,795 (in thousands), compared with $52,876 (in thousands) for the three months ended June 30, 2025.$48.80M––
Professional servicesProfessional services revenue was $21,692 (in thousands), compared with $27,845 (in thousands) for the three months ended June 30, 2025.$21.69M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Third quarter of 2026 and full year of 2026 outlook

  • Revenue$55 million to $56 million for the third quarter of 2026; $246 million to $249 million for the full year of 2026
  • NoteAdjusted EBITDA of $0 to $0.5 million for the third quarter of 2026
  • NoteAdjusted EBITDA of $18 million to $18.5 million for the full year of 2026

What drove it

  • Gross margin was 40%, compared with 38% in the prior-year period.
  • Adjusted Gross Margin was 51%, compared with 50% in the prior-year period.
  • Adjusted EBITDA was $9,919 (in thousands), compared with $9,344 (in thousands) in the prior-year period.
  • Sales and marketing expense was $10,360 (in thousands), compared with $13,206 (in thousands) in the prior-year period.
  • Research and development expense was $11,026 (in thousands), compared with $12,392 (in thousands) in the prior-year period.
  • Management stated that second-quarter revenue exceeded the high end of its revenue guidance and adjusted EBITDA exceeded the midpoint of its adjusted EBITDA guidance.

Concerns

  • Total revenue declined (13)% year over year.
  • Technology revenue was $48,795 (in thousands), compared with $52,876 (in thousands) in the prior-year period.
  • Professional services revenue was $21,692 (in thousands), compared with $27,845 (in thousands) in the prior-year period.
  • The company reported a GAAP net loss of $ (40,537) (in thousands) and loss from operations of $ (36,480) (in thousands).
  • Goodwill impairment was $27,047 (in thousands).
  • Third-quarter 2026 total revenue guidance is $55 million to $56 million and adjusted EBITDA guidance is $0 to $0.5 million.
  • The company identified risks including client churn or down-selling in connection with migration to Ignite, project-based non-recurring revenue fluctuations, and the possibility that the Vitalware divestiture may not achieve expected benefits.

What to watch

  • Delivery against third-quarter 2026 total revenue guidance of $55 million to $56 million.
  • Delivery against third-quarter 2026 Adjusted EBITDA guidance of $0 to $0.5 million.
  • The impact of the Vitalware divestiture on the company’s business, liquidity, and financial results.
  • Technology and professional services revenue trends.
  • The balance-sheet effects of the stated full repayment of the credit facility debt.

Balance sheet and cash flow

  • Cash and cash equivalents were $60,589 (in thousands) as of June 30, 2026, compared with $50,814 (in thousands) as of December 31, 2025.
  • Short-term investments were $42,850 (in thousands) as of June 30, 2026, compared with $44,918 (in thousands) as of December 31, 2025.
  • Assets held for sale were $91,424 (in thousands) as of June 30, 2026.
  • Current portion of long-term debt was $1,627 (in thousands) as of June 30, 2026.
  • Long-term debt, net of current portion, was $151,852 (in thousands) as of June 30, 2026.
  • Total stockholders’ equity was $100,827 (in thousands) as of June 30, 2026, compared with $245,780 (in thousands) as of December 31, 2025.
  • Management stated that it recently closed the Vitalware divestiture and fully repaid its credit facility debt.

Analysis

Health Catalyst’s second-quarter results showed lower revenue but improved reported gross-margin measures and adjusted EBITDA. Total revenue was $70,487 (in thousands), down (13)% from $80,721 (in thousands). Technology revenue was $48,795 (in thousands), compared with $52,876 (in thousands), while professional services revenue was $21,692 (in thousands), compared with $27,845 (in thousands). Both reported revenue lines were lower than in the prior-year quarter.

Margins improved despite the revenue decline. GAAP gross margin was 40%, compared with 38%, and Adjusted Gross Margin was 51%, compared with 50%. Adjusted EBITDA increased 6% to $9,919 (in thousands) from $9,344 (in thousands). Lower sales and marketing expense and research and development expense were reported relative to the prior-year period, while general and administrative expense increased to $11,928 (in thousands) from $8,284 (in thousands).

GAAP profitability remained pressured. The company reported loss from operations of $ (36,480) (in thousands) and net loss of $ (40,537) (in thousands), with a $27,047 (in thousands) goodwill impairment recorded during the quarter. The net loss was slightly narrower than $ (40,978) (in thousands) a year earlier, and basic and diluted net loss per share was $ (0.55), compared with $ (0.59). The company also reported $1,958 (in thousands) of acquisition-related costs, net, compared with $ (3,720) (in thousands) in the prior-year quarter.

Balance-sheet disclosures reflect $60,589 (in thousands) of cash and cash equivalents, $42,850 (in thousands) of short-term investments, $1,627 (in thousands) of current long-term debt, and $151,852 (in thousands) of long-term debt, net of current portion, as of June 30, 2026. Management subsequently stated that the Vitalware divestiture had recently closed and that the credit facility debt had been fully repaid. The June 30 balance sheet also included $91,424 (in thousands) of assets held for sale and total stockholders’ equity of $100,827 (in thousands).

Management said second-quarter revenue exceeded the high end of its guidance and adjusted EBITDA exceeded the midpoint of its guidance. The forward outlook calls for third-quarter total revenue of $55 million to $56 million and Adjusted EBITDA of $0 to $0.5 million, followed by full-year total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million. The central issues for the next period are execution against that lower absolute quarterly revenue range, the trajectory of technology and professional services revenue, and the realized balance-sheet and operating effects of the Vitalware divestiture.

Management, verbatim

We delivered a very productive second quarter, exceeding the high end of our revenue guidance and the midpoint of our adjusted EBITDA guidance.

Ben Albert, Chief Executive Officer of Health Catalyst

More importantly, we recently closed the Vitalware divestiture and fully repaid our credit facility debt, which significantly improves our balance sheet and provides flexibility to make measured near-term bets in the work we believe in most.

Ben Albert, Chief Executive Officer of Health Catalyst

Not in the filing

stated, not guessed
  • Previous-period outlook, so reported results cannot be compared with prior guidance in a structured guidance comparison.
  • Operating cash flow.
  • Free cash flow.
  • Capital-return disclosures, including share repurchases and dividends.
  • Adjusted EPS.
  • Forward guidance for gross margin, operating expenses, and tax rate.
  • Quarter-over-quarter comparisons for reported metrics.
  • Reported year-over-year growth rates for Technology revenue and Professional services revenue.
  • CFO commentary.
  • A reconciliation of forward Adjusted EBITDA guidance to GAAP net loss, which the company stated it did not provide.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about HCAT earnings dates

When is Health Catalyst's next earnings date?
AlphAI has no date for HCAT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.